FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients
Oncopeptides has submitted a new drug application to…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
1,066 Myeloma Patients Answer HealthTree Survey of COVID-19’s Effects
Over some four weeks, 1,066 people with multiple myeloma took…
FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
The U.S. Food and Drug Administration (FDA) has…
Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease…
Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo
The combination therapy of melflufen (melphalan flufenamide) and…
Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials
Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate,…
